ArticleOphthalmology and therapy2025
Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME.Journal of clinical medicine · 2026Review
- Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab.Journal of clinical medicine · 2026Article
- Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to assess the morphological and functional effects of faricimab in patients with chronic diabetic macular edema (DME) who had an insufficient response to previous treatments.
methodsWe conducted a single-center, retrospective study including eyes with pretreated chronic DME that were switched to faricimab and received at least three injections. The main outcome measures were central subfield thickness (CST) and best-corrected visual acuity (BCVA) changes before and after switching to faricimab.
resultsTwenty-two eyes from 18 patients were analyzed, with a mean pretreatment period of 5.7 years. Most eyes had been treated with two or more intravitreal agents. Before switching to faricimab, the mean CST was 468.5 ± 163.6 µm, which decreased to 383.1 ± 125.3 µm, 362.8 ± 93.4 µm (p = 0.207), and 339.5 ± 94.3 µm (p < 0.001) after the first, second, and third injections, respectively. BCVA showed improvement from 0.48 to 0.37 logMAR after the third injection, though the change was only statistically significant after the first injection (p = 0.022).
conclusionsThe study demonstrated significant CST reduction in patients with chronic DME in a real-world setting, even after prolonged treatment, suggesting that faricimab can lead to morphological and functional benefits in these cases. Further data are needed to explore the real-world, long-term effects and durability of faricimab in chronic DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.